Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

BACKGROUND: Fingolimod is a S1P(1) receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes. Withdrawal from fingolimod can be followed by severe disease reactivation, and this coincides with return of autoreactive ly...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado, Silvia, Hernandez, Jeffrey, Tornes, Leticia, Rammohan, Kottil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851905/
https://www.ncbi.nlm.nih.gov/pubmed/33530945
http://dx.doi.org/10.1186/s12883-021-02058-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851905/
https://www.ncbi.nlm.nih.gov/pubmed/33530945
http://dx.doi.org/10.1186/s12883-021-02058-2

Ejemplares similares